Bristol-Myers Squibb reports presentation of hematology data at EHA

The FINANCIAL — Bristol-Myers Squibb Company on June 11 announced the presentation of clinical research from its hematology portfolio at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria from June 11-14. Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.

Data to be presented at EHA exemplify Bristol-Myers Squibb’s commitment to advancing the treatment of blood cancers through its experience in hematology and its transformative science of Immuno-Oncology.

Key oral presentations include:

ELOQUENT-2: A Phase 3, open-label study [Abstract #S471] comparing elotuzumab in combination with lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone alone (Ld) in patients with relapsed or refractory multiple myeloma, will be featured in the EHA press briefing on Friday, June 12 at 8:30 a.m. CEST and will be presented during the Presidential Symposium, also on June 12, at 3:45 p.m. CEST. The ELOQUENT-2 study was published in the New England Journal of Medicine on June 2.

Study 009: A Phase 2, open-label study [Abstract #S103] comparing elotuzumab in combination with bortezomib (a proteasome inhibitor) and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma will be presented in an oral session on June 12 at 12:00 p.m. CEST.

PREAMBLE: A preliminary analysis of an ongoing, multinational, observational study [Abstract #S148] evaluating the real-world clinical effectiveness of standard treatments, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), in patients with relapsed or refractory multiple myeloma will be presented in an oral session on June 12 at 12:00 p.m. CEST.

CheckMate -039: Updated data from a Phase 1 study [Abstract #S808] evaluating the safety, tolerability and potential efficacy of Opdivo in several hematologic malignancies, including classical Hodgkin Lymphoma will be presented in an oral session on Sunday, June 14 at 8:45 a.m. CEST.

“Bristol-Myers Squibb is leveraging its broad experience in oncology and leading Immuno-Oncology science to develop a portfolio of innovative therapies, including a novel modality for multiple myeloma, because we believe patients with blood cancers deserve more,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. “These data at EHA illustrate our commitment to transforming survival expectations for more patients with a variety of hematologic malignancies.”